Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 15,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Not applicable Interventional

Campus Life Study: Harnessing Generativity Among Young Adults

NCT04207528
View directory record Official record
Conditions
Healthy Young Adults
Interventions
Writing
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

NCT01587365
View directory record Official record
Conditions
Atherosclerosis
Interventions
BMS-962476, Placebo matching with BMS-962476
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

NCT04419467
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
CSL346, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
25 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Fresno, California • Lomita, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 29, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 29, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement

NCT07453693
View directory record Official record
Conditions
UTI's
Interventions
FLUSH
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

NCT06345404
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Soquelitinib, Placebo
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

NCT02032004
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Rexlemestrocel-L, Sham Comparator
Biological · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Gilbert, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional

A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder

NCT00232414
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 29, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional

Taste Alterations Study

NCT06669416
View directory record Official record
Conditions
Chemotherapy Side Effects, Taste, Altered
Interventions
Taste Alteration Self-Assessment, Taste Alternation Self-Management
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Placebo
Drug
Lead sponsor
Resolvyx Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2010 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Birth Control Use After Childbirth

NCT01443533
View directory record Official record
Conditions
Contraception
Interventions
LARC Script
Behavioral
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

NCT04502693
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
3,657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional

Controlled Trial of Valacyclovir in Infectious Mononucleosis

NCT00274404
View directory record Official record
Conditions
Infectious Mononucleosis
Interventions
valacyclovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 29, 2026, 5:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Garetosmab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

NCT05568706
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Adult - Chiron Study of Bird Flu Vaccine

NCT00280033
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia

NCT02516306
View directory record Official record
Conditions
Presbyopia
Interventions
EV06 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Encore Vision, Inc.
Industry
Eligibility
45 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Artesia, California • Mission Hills, California • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 29, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

NCT06527404
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT00889252
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
contact lens with ketotifen, contact lens
Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 29, 2026, 5:41 PM EDT
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder

NCT00390533
View directory record Official record
Conditions
Generalized Anxiety
Interventions
Saredutant, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 29, 2026, 5:41 PM EDT